0001567619-20-013993.txt : 20200803 0001567619-20-013993.hdr.sgml : 20200803 20200731181810 ACCESSION NUMBER: 0001567619-20-013993 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200803 DATE AS OF CHANGE: 20200731 EFFECTIVENESS DATE: 20200803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncternal Therapeutics, Inc. CENTRAL INDEX KEY: 0001260990 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621715807 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-372298 FILM NUMBER: 201067277 BUSINESS ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 434-1113 MAIL ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: GTX INC /DE/ DATE OF NAME CHANGE: 20030822 D 1 primary_doc.xml X0708 D LIVE 0001260990 Oncternal Therapeutics, Inc. 12230 El Camino Real Suite 300 San Diego CA CALIFORNIA 92130 (858) 434-1113 DELAWARE None GTX INC /DE/ Corporation true James B. Breitmeyer, M.D., Ph.D. c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director Executive Officer President and Chief Executive Officer Richard Vincent c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Executive Officer Chief Financial Officer Igor Bilinsky, Ph.D. c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Executive Officer Chief Business Officer Frank Hsu, M.D. c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Executive Officer Chief Medical Officer Gunnar F. Kaufmann c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Executive Officer Chief Scientific Officer Hazel M. Aker c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Executive Officer General Counsel David F. Hale c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director Michael G. Carter, M.D., ChB, FRCP c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director Daniel Kisner, M.D. c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director William R. LaRue c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director Xin Nakanishi, Ph.D. c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director Charles Theuer c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director Robert Wills, Ph.D. c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director Man Cho c/o Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 300 San Diego CA CALIFORNIA 92130 Director Biotechnology Decline to Disclose 06b false 2020-07-17 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue New York NY NEW YORK 10022 All States false Rodman & Renshaw, LLC 281264 None None 430 Park Avenue New York NY NEW YORK 10022 All States false 3456308 3456308 0 Represents warrants to investors to purchase up to 1,290,933 common shares @ $2.32/share, warrants to H.C. Wainwright Co. and Rodman & Renshaw to purchase up to 154,912 common shares @ $2.9781/share, in connection with the registered direct offering. false 12 381336 0 H.C. Wainwright was paid a total of $381,336.38 and warrants to purchase 154,912 shares of common stock at $2.9781 per share. 0 false Oncternal Therapeutics, Inc. /s/ James B. Breitmeyer, M.D., James B. Breitmeyer, M.D., Ph.D. President and Chief Executive Officer 2020-07-31